INSULIN RESISTANCE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 在前列腺癌患者中，使用促性腺激素释放激素激动剂治疗会增加患糖尿病和心血管疾病的风险。短期的促性腺激素释放激素激动剂治疗降低了胰岛素敏感性，这表明与治疗相关的胰岛素抵抗可能导致前列腺癌男性患者患糖尿病和心血管疾病的风险。后一种观察结果提出了两个主要问题。首先，长期治疗对胰岛素敏感性有什么影响？第二，停药后胰岛素敏感性的改变可逆吗？这项研究试图解决这两个问题。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In men with prostate cancer, treatment with a GnRH agonist is associated with increased risk of diabetes mellitus and cardiovascular disease. Short-term GnRH agonist treatment decreases insulin sensitivity, suggesting that treatment-related insulin resistance may contribute to risk of diabetes and cardiovascular disease in men with prostate cancer. Two main questions arise from the latter observation. First, what are the effects of longer-term treatment on insulin sensitivity? Second, are the changes in insulin sensitivity reversible after discontinuation of treatment? This study will attempt to address both questions.